Compare SIND & MPLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIND | MPLT |
|---|---|---|
| Founded | N/A | 2018 |
| Country | | United States |
| Employees | N/A | 133 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.7B |
| IPO Year | N/A | N/A |
| Metric | SIND | MPLT |
|---|---|---|
| Price | $16.20 | $12.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $32.67 |
| AVG Volume (30 Days) | 99.9K | ★ 1.4M |
| Earning Date | N/A | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.03 | $9.10 |
| 52 Week High | $16.37 | $40.43 |
| Indicator | SIND | MPLT |
|---|---|---|
| Relative Strength Index (RSI) | 70.47 | 28.72 |
| Support Level | $11.88 | $11.56 |
| Resistance Level | N/A | $20.73 |
| Average True Range (ATR) | 1.44 | 2.03 |
| MACD | 0.28 | -1.11 |
| Stochastic Oscillator | 93.98 | 11.12 |
Sinda Ltd is an exploration stage company focused on acquiring, exploring, and developing mineral concessions in Mexico. The company holds mining concessions and exploration and exploitation rights for a silver-gold project located in the Guanajuato silver belt of Mexico. Its principal asset is the Sinda Property, a silver project at the exploration stage.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.